raenderle
Member
Though this would be interesting especially for those who have warfarin-related hemorrhage problems like me
The St. Jude valve: Analysis of thromboembolism, warfarin-related hemorrhage, and survival
[/U]
Lawrence S.C. Czer M.D., a, b, Jack M. Matloff M.D.a, b, Aurelio Chaux M.D.a, b, Michele De Robertis R.N.a, b, Morgan E. Stewart Ph.D.a, b and Richard J. Gray M.D.a, b
aDepartment of Thoracic and Cardiovascular Surgery, Cedars-Sinai Medical Center Los Angeles, Calif., USA
In conclusion
, warfarin anticoagulation is recommended in all patients. Although the operative and late survival rates reported in this study reflect in part the inclusion of high-risk patients with advanced functional class, left ventricular dysfunction, and ischemic mitral regurgitation, a major cause of valve-related morbidity and late death was warfarin-related hemorrhage A downward revision in the target prothrombin time ratio to 1.5 to 2.0 may result in fewer bleeding complications The optimal antithrombotic regimen in children remains to be defined.
Abstract
From March 1978–1986, 590 St. Jude prostheses (232 aortic, 232 mitral, and 63 double aortic-mitral) were implanted in 527 patients (mean age 63 years) and followed for up to 8 years (mean 33 months; three lost; 99% complete). The early (30-day) mortality rate was 8.9% and was strongly associated with preoperatively depressed left ventricular function (ejection fraction <0.55), ischemic mitral regurgitation, and advanced functional class (IV) (p < 0.05). Actuarial survival rates at 5 years were 72% ± 4%, 72% ± 8%, and 63 ± 4% after aortic, double, and mitral valve replacement (p < 0.01).
There have been no structural failures. Embolism (28 events, 2.1%/patient-year) was less common with warfarin treatment (1.5%/patient-year; n = 492) than with antiplatelet (3.2%/patient-year; n = 19) or no drug therapy (18.9%/patient-year; n = 16) (p < 0.01). One embolic event was fatal (3.6%). Warfarin-treated patients remained 91% ± 1% free of emboli after 8 years. Valve thrombosis (six events; 0.4%/patient-year) occurred exclusively in patients not treated with effective warfarin therapy; one (17%) died. The most common complication was hemorrhage (39 events; 2.9%/patient-year); nine (23%) were fatal, and these constituted 82% of 11 valve-related late deaths. In warfarin-treated patients (target prothrombin time ratio 1.5 to 2.5), hemorrhage was twice as frequent (2.9%/patient-year) as embolism (1.5%/patient-year).
The link can be found at...
http://www.sciencedirect.com/scienc...0431bda6206fe5e259dd75451ce375ad&searchtype=a
Cheers
Richard
The St. Jude valve: Analysis of thromboembolism, warfarin-related hemorrhage, and survival
[/U]
Lawrence S.C. Czer M.D., a, b, Jack M. Matloff M.D.a, b, Aurelio Chaux M.D.a, b, Michele De Robertis R.N.a, b, Morgan E. Stewart Ph.D.a, b and Richard J. Gray M.D.a, b
aDepartment of Thoracic and Cardiovascular Surgery, Cedars-Sinai Medical Center Los Angeles, Calif., USA
In conclusion
, warfarin anticoagulation is recommended in all patients. Although the operative and late survival rates reported in this study reflect in part the inclusion of high-risk patients with advanced functional class, left ventricular dysfunction, and ischemic mitral regurgitation, a major cause of valve-related morbidity and late death was warfarin-related hemorrhage A downward revision in the target prothrombin time ratio to 1.5 to 2.0 may result in fewer bleeding complications The optimal antithrombotic regimen in children remains to be defined.
Abstract
From March 1978–1986, 590 St. Jude prostheses (232 aortic, 232 mitral, and 63 double aortic-mitral) were implanted in 527 patients (mean age 63 years) and followed for up to 8 years (mean 33 months; three lost; 99% complete). The early (30-day) mortality rate was 8.9% and was strongly associated with preoperatively depressed left ventricular function (ejection fraction <0.55), ischemic mitral regurgitation, and advanced functional class (IV) (p < 0.05). Actuarial survival rates at 5 years were 72% ± 4%, 72% ± 8%, and 63 ± 4% after aortic, double, and mitral valve replacement (p < 0.01).
There have been no structural failures. Embolism (28 events, 2.1%/patient-year) was less common with warfarin treatment (1.5%/patient-year; n = 492) than with antiplatelet (3.2%/patient-year; n = 19) or no drug therapy (18.9%/patient-year; n = 16) (p < 0.01). One embolic event was fatal (3.6%). Warfarin-treated patients remained 91% ± 1% free of emboli after 8 years. Valve thrombosis (six events; 0.4%/patient-year) occurred exclusively in patients not treated with effective warfarin therapy; one (17%) died. The most common complication was hemorrhage (39 events; 2.9%/patient-year); nine (23%) were fatal, and these constituted 82% of 11 valve-related late deaths. In warfarin-treated patients (target prothrombin time ratio 1.5 to 2.5), hemorrhage was twice as frequent (2.9%/patient-year) as embolism (1.5%/patient-year).
The link can be found at...
http://www.sciencedirect.com/scienc...0431bda6206fe5e259dd75451ce375ad&searchtype=a
Cheers
Richard